The Priority Review

Tag

Stream

353 stories · page 19 of 30

Stories

  1. Clinical trials

    Pfizer registers Phase 3 study of RSVpreF revaccination in OLDER ADULTS

    Pfizer has registered a Phase 3, randomized, OPEN-LABEL study to EVALUATE the safety and tolerability of a second dose of RSVpreF given approximately 5 years after the initial dose. The study plans to enroll 750 participants, start on October 29, 2026, and reach primary completion on February 7, 2029.

  2. Clinical trials

    Seagen posts results of Phase 3 ECHELON-3 trial of brentuximab vedotin in relapsed/refractory DLBCL

    The study enrolled 240 participants and compared brentuximab vedotin plus lenalidomide and rituximab to placebo plus lenalidomide and rituximab. Results were first posted on ClinicalTrials.gov on October 21, 2026.

  3. Clinical trials

    Gilead posts results of ARTISTRY-1 bictegravir/lenacapavir study

    The study, enrolling 689 participants, compared bictegravir/lenacapavir to stable baseline regimens in virologically suppressed people with HIV-1. Results were first posted on ClinicalTrials.gov on October 21, 2026.

  4. Approvals

    FDA approves once-weekly generic hormone therapy patch for women

    The FDA approved the first generic of Climara Pro, a transdermal estradiol and levonorgestrel system (0.045 mg per day/0.015 mg) applied once a week for women with an intact uterus. The generic is therapeutically equivalent to Climara Pro and the most common adverse reactions are application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome (≥5 %).

  5. Approvals

    FDA approves first-of-its-kind chronic hepatitis B treatment

    The FDA approved Hibsago (bepirovirsen) injection for adults without cirrhosis who have been on antiviral therapy for at least six months and have HBsAg levels of 3,000 IU/mL or less. The approval includes the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic.

  6. Clinical trials

    Amgen and AstraZeneca report Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis

    The Phase 3 CROSSING trial showed TEZSPIRE achieved histologic remission in 64.8% (210 mg) and 68.9% (420 mg) of patients at week 24 versus 3.5% on placebo (p<0.001). The Dysphagia Symptom Questionnaire score decreased by 18.8 points (210 mg) and 22.0 points (420 mg) versus 14.7 points on placebo, with reductions sustained through week 52.

  7. Clinical trials

    GC Biopharma registers Phase 2/3 trial of GC3114B in adults 65 years or older

    The study plans to enroll 1806 participants and is expected to begin in October 2026. It is a multicenter, randomized, double-blind, active-controlled trial that will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.

  8. Clinical trials

    Janssen posts results of Phase 3 ustekinumab trial in pediatric ulcerative colitis

    The study, completed in 2025, enrolled 112 pediatric participants with moderately to severely active ulcerative colitis and evaluated ustekinumab induction and maintenance therapy. Results were first posted on ClinicalTrials.gov on October 20, 2026.

  9. Regulation

    FDA issues final guidance on prescription drug apps and software

    The FDA released final guidance on October 20, 2026 that clarifies when app content is subject to FDA submission requirements and when it should be mentioned on a drug's official label. The guidance identifies two categories of companion software-apps connected to a medical device and standalone apps-and sets conditions for labeling and what companies should submit to the agency.

  10. Regulation

    FDA releases guidance on new dietary ingredient notifications

    The Food and Drug Administration announced the availability of final guidance titled "New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry." The guidance addresses frequently asked questions and provides recommendations for manufacturers and distributors on the identity and safety information that should be included in an NDIN.

  11. Approvals

    FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer

    On October 19, 2026 the FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient. The approval was based on AZUR-1, a single-arm trial of 154 patients that reported a 47% sustained clinical complete response at 12 months per independent central review.

  12. Clinical trials

    DelveInsight reports KRAS inhibitors market to grow positively by 2036

    DelveInsight said the total KRAS inhibitors market size is expected to grow positively by 2036, driven by therapies such as Divarasib (RG6330), Olomorasib (LY3537982) and MK-1084. The company noted the United States accounted for the largest market share in 2025, with 539,400 incident NSCLC cases.